VYGR - Earnings call transcript Q2 2024 | Voyager Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Voyager Therapeutics Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] There will be a question-and-answer session at the end of this call. Please note that today's call is being recorded. A replay of today's call will be available on the Investors section of the company website approximately 2 hours after completion of this call. I would now like to turn the call over to Trista Morrison, Chief Corporate Affairs Officer at Voyager.

Trista Morrison

Thank you, and good afternoon. quarter results second afternoon. release our issued XXXX press financial this We press available are and our The XX-Q on release website.

Medical Toby Joining Dr. me Officer. our Dr. Chief Al are Dr. Chief Ferguson, Sandrock, our Jorgensen, on Chief Executive Financial today's our Officer; and call Nathan Officer;

by also will call for Carter, our portion of the We Todd Q&A Chief joined the be Dr. Scientific Officer.

may today's in website I'd and to like based current additional will I results during the consult actual These may Voyager to representatives detail. And our call that Slide are to and this noted as factors of everyone turn started, you make remind over risk get our encourage on in statements we discussed I are for expectations deck. risks They the which uncertainties SEC Before now, statements and X differ forward-looking are Al. our call, to filings, materially. our beliefs. on subject available

Alfred Sandrock

turn joining transformative medicines Good afternoon, of diseases. develop to and everyone, the Please the discover leveraging we human and X. for genetics power that thank us. Voyager, are At cause to neurological of root you address Slide

on in will in expect bit. first Alzheimer's in the and formerly detail in Enrollment made to VY-TAUXX, next May, data safety tau volunteers this line of and goal the this We several of is Phase top called pharmacokinetic antibody pathological of half progress Ia quarter. the to additional disease. our we spread in trial second in including just the year. Toby report VYXXXX, important on our dose XXXX, tremendous study have dosed programs of toward the inhibit track a healthy we milestones the In achievement tau-directed first provide ascending designed single anti-tau in

wholly-owned $X a and silencing quarter, FDA meeting second filings gene Voyager. development breadth seeing the year. in CNS June, ataxia. In operational our appointed occurred Neurocrine for expect first This we financial a to Jorgensen initiated in of We wholly-owned SODX completed Voyager. million these and advance candidate Officer therapy Friedreich's milestone care Also selection differentiated X and for the partner investment already with for we selected of to Nathan pre-IND for with quarter, program investing, payment next In therapy pipeline roles this that the continue in triggering experience banking, gene on therapy GBAX Nate studies the candidate IND Financial of neuroscience. Neurocrine, leadership continue we I'm follows as programs his benefits brings quarter development PhD a program program VYXXXX, in therapy partnered ALS. gene of of our a robust Chief and gene our a to health strategic programs highly GLP spanning biotech partnered expertise. toxicology we SODX our

posters and Our evidenced body team targets XXXX receptor and TRACER ALS. in case presented data available presentations website you Alzheimer's against capsids, therapeutic our cross May, translatability at and activity by These them. data second-generation in of on and species in data as their an our ASGCT disease impressive are missed on including

second provide progress Finally, we $XXX data which pillars our approximately on plans, in X with of quarter are based of cash our we the clinical into which Slide expect current we into XXXX. The strong ended value, readouts feeds quarter a on million, position to operating through outlined second made X. runway the multiple

our partnered programs. of X and First is wholly-owned XX pipeline

XXXX up data a dose antibody, is VYXXXX and INDs anti-tau readouts potential for year. trial next XXXX. have I to and in mentioned, in our single therapies gene we sets X As ascending tracking This multiple

TRACER industry-leading platform gene AAV therapy. capsids novel of to our enable CNS for is Second discovery the

CNS key our development candidates second-generation reinforced, transduction multiple and enabled a of As significant of detargeting programs. single selection ASGCT IV gene in liver data we wholly-owned have These and the the dose. have robust capsids cell our presented types capsids following partnered demonstrated therapy

we neurology gene our Novartis In up Neurocrine, in world's partnered including in partnerships programs could and Third, some and longer-term payments. Alexion. with experts therapy, $X.X of have the generate milestone to billion total, blue-chip

we therapy that, the to leverage modalities share gene his Finally, programs. over the expand medicines conviction we into to continue call other and our gene Toby and the explore our we have to brain. from of genetic medicine, to into broadening shuttle therapy I'll potential identified receptors turn antibodies non-viral impact. With to to on tau Ultimately, neurogenetic aim

Toby Ferguson

to programs that turn spend all afternoon. the our some to We programs. and but Please mentioned won't earlier. summarizes X slide and today, of wholly-owned a Al, programs programs Thanks, want these on Al of minutes Slide X. few I This advanced partner more good do XX discuss

is Alzheimer's to wholly-owned Turning X that are believe tau our to I Slide for programs X. critically a the of for want we disease. important tau. moment on treatment that focus a reasons few target There

First, brain the presence is disease. defining feature the pathology of of the a tau in

to can likely that to be disease. provided readily tau PET of spread correlates wealth in visualized third, a enrollment the clinical imaging, quantitative spread of appropriate And is and in tau readout a outcomes. accumulation individuals the that Second, vivo clinical with predict the evidence the of enabling with pathology studies biological tau clinical closely pathology blade decline and demonstrates of in Alzheimer's

antibodies in tau directed VYXXXX that N-terminal showed In anti-tau is data clinic the outcomes. an tau advancing spread complementary called epitope favorable approaches the of to are generated of Importantly, inhibit cell-to-cell Alzheimer's spread clinical a XX%, of reducing model. with have anti-tau in using we was approaches human targeted N-terminal tau reduce designed in unsuccessful the an pathological and expression tau ineffective tau. In had recent model were C-terminal surrogate At third-party to intrathecally antibody trends spread, brain. on to the of VYXXXX, associated approximately vivo the in contrast a the clinic. tau VYXXXX, of administered pathological [indiscernible] been an X antibody in ineffective formerly the also tau-directed third-party in that by VY-TAUXX targets were tau while Voyager, clinical pathology inhibit antisense disease. oligonucleotide

This study multiple conduct the quarter, Phase double-blind early cohorts. of the of to randomized the we to line dose next track VYXXXX pharmacokinetics at participants trial single XX This Enrollment to year. We participants Alzheimer's multiple Ia the safety in first in and expect in trial half trial approximately then disease. is ascending is and ascending on data of with we evaluate this VYXXXX participant report placebo-controlled healthy designed plan in volunteers. top dose in a across dosed first

imaging we've human believe across capsid. tau protein half transformative mRNA demonstrated Tau for a Using brain of approach, provide XXXX. to the generate show to approach, deploys the We this single-treatment second mice expect That the are we data robust and TRACER potential in to program This and initiate in Therapy has Alzheimer's slowing this Complementing of and this Gene reductions single tau XXXX. following program. tau. a an IND the also filing spread. trial next siRNA Silencing in administration an human has a We a program antibody-based year tau-targeted packaged IV in we advancing IV-administered expressing anticipate this initial potential in tau disease

Turning to Slide X.

the which gene wholly-owned Neurocrine ataxia ataxia we're program program, programs gene of partnered for VYXXXX, cause tau, the GBAX-mediated ] [ and to cause IND and In a other targeting Parkinson's Neurocrine of placement replacement Friedreich's the therapy SODX-ALS. targeting The GBA genetic partnered program disease Friedreich's X advancing include our silencing for also programs genetic targeting SODX expect year. filings we addition They next diseases.

XEXX reminder, a at spinal cord have dose reduced of we As a SODX VYXXXX demonstrated IV single kilogram non-human administration that genomes motor in to mRNA in up vector of per clinically neurons XX% relevant a primates. the

aim the of validated proof spinal trial IND in in levels biomarkers in Consistent of strategy generate programs, next year and the of file VYXXXX patients progression in for biology of levels fluid cerebral plasma. to our target our assess and to disease including measured expect SODX-ALS this engagement the SODX in the clinical and we trial, neurofilament IND of middle clinical to with rapid is in We an after accepted. initiate

TRACER Importantly, I'll to CNS gene the to turn program that, derisk Nate. the our data further has therapy first could gene generate since we over it employing clinical pipeline. With therapy broader capsid, this the call a potential for believe

Nathan Jorgensen

grateful team. Voyager just I say here be to a the Toby. Thanks, I'm today that to and want of to member be

in in company background neuroscience sell the on and my my I CFO, diseases with the unlocked risk. CNS well the the Given as public familiar treating buy side, remaining a be experience and to deeply as tremendous value as am side

of by the risk, Voyager that spend thereby transformative the I the by that to substantial company enable and increase risk risk risk hurdles outlined potentially across level an reducing internal focusing proof of this biomarkers the R&D have delivery see path risk to delivery strategy. the the elements create genetics. was development disease and barrier. derisking efficient partnering level that the at probability reduce share at value value reasons I one, succeed biology is at programs by I near-term level reducing to overcome maintaining way will level programs target X, one, blood in And reducing heart, Number Slide to by One its my that creation. three, clinical aimed clinic. On working I this clinical two, targets pipeline at and compelling posed Number and human joined X upside. systematically by financial reducing platform an selectively reduce to the dear as validated appreciated brain while the pioneering industry-leading on areas of And by the what risk focusing on

at and challenges the believe overcome uniquely back forward of the unparalleled and tremendous shareholders. conferences neuroscience experts to please I and hesitate many Voyager I Given pass look neurology create Al. fundamental in to not you value out of any to drug that, I'll Voyager's and reach over high to and do in in positioned need is both questions. With unmet investor space upcoming with team it connecting events for neuro patients development, with

Alfred Sandrock

Thanks, Nate.

deliver XXXX. on see you expectations continues As Voyager on Slide X, can for to

both XX cash we Voyager term. well believe our leadership to is XX a our months, milestones in team. XXXX, over With near $XXX strengthened maturing runway expected value and creation and a We partnership have and collaborators our public with partnerships advanced poised of million pipeline, platform into clinical significant and drive next long as robust top-tier to a executed our the portfolio offering slate as the

for and dedication Finally, call Operator? of we lives that, all of I'd work for thank hard the improving the patients. With will open our like to employees to their questions.

Operator

Instructions] question First with Baird. comes Jack [Operator Allen from

Jack Allen

others? to as to it love thoughts how to it Do over here I'd lost I hear But I Ohio. quickly we it power there? could made was relates where the impact progress of in wanted can coming the compared you cadence are therapy course months see quarter. ASO's internally program, it about I a which expected And that I therapy am enter early of more SODX-ALS of matter and a [indiscernible], be from quick relates to clinic of in out internal the sense ask the XXXX. the on how for gene impact. of programs have on your as that I may then gene programs or to think we relates look advanced weeks biomarkers the the effect Congratulations actually apologize, in as those to to at as that's the owned. I indications of X was

Alfred Sandrock

the I'll second and ask Thanks, answer to is This Al. Jack. then start question. I'll Toby

the I cadence, and that hopefully, And So to trials. we therapy are of the wholly-owned control expect the mid-XXXX thereafter in shortly SODX time in gene file in frame. and terms our one FDA IND get in we roughly we'll program of mean, is we through process thing start can sales an clinical

well. other know in Toby? In than I our they partnered IND that, expect other that programs, say can those We I'm the as terms to of about But from are more partners file programs. not cadence. certain the XXXX

Toby Ferguson

thanks for the Jack, question.

I think you've got the idea correct.

be a saw of neurofilament and also can can us measure program fundamentally, target neurofilament changes remind think there. that at. we a reduction measuring about at first you the engagement the And looking can looking and in SOD XX% the SODX observed Biogen by also taught you SODX to we'll understand observe that's see you effective CSF of reduction, biomarker would to -- has with change the tofersen be I that program CSF course,

Jack Allen

the just Biogen was quickly that light could trying in to for effect in efficacy. how indications chain SODX on Maybe quickly see really Toby, I'm how we early a sense seen briefly, neurofilament setting? of get

Toby Ferguson

weeks, by neurofilament So Biogen reach they'd By XX fundamentally, be administered X weeks. started intrathecally to observed to ASO. ]. XX remember, their is Those natter changes [

different gene to time of through course, need this administering lines I an therapy so think that. here We, we though ASO. may are make be the point and is work those is to and

Alfred Sandrock

And what about SODX? the

Toby Ferguson

that seen for be And really SODX. weeks can SODX, but the effect early as is think be XX you X in when I really see to as weeks, starting start seen to

Jack Allen

Congratulations queue. on back progress. I'll the jump in

Operator

next The question Rao from TD Instructions] [Operator Cowen. Divya with comes

Divya Rao

models VYXXXX. is have idea on that I far, to I us considered Divya think exploring? hit question. for you be One based you're you give would is Could many have how an This an for of X Phil. dose doses a how questions. the through dose? preclinical follow-up active on have many And just so you And then do what cut you then levels

Toby Ferguson

we're the ascending at Fundamentally, to Toby. volunteers, Divya, doses doses. multiple for thanks healthy is question. looking the remind in This single

but think get the the we exposures we understand frankly, based on we SOD the study tau with disclosed a models move data, spread, on We spread. And exposures MAD think preclinical next need to and haven't forward we year. we will measure understand those, based that tau those

Alfred Sandrock

Todd, part? to answer the second do you want

Todd Carter

able the tau better for What question able to that of pathology to to off we to. and models. that being, achieve something relative basing know the we're we've we're reduction modeling it Toby part second model the approximately referred the our doses the are that [indiscernible] So, the or PK XX% to is be done what of knockdown, in we expect studies a preclinical of achieve

is doing the in our CNS achieve achieve we the that that patients knockdown. antibody brain to needed of to we're that we're level in aiming of what exposure level XX% So, the to

our So, on dosing is based correlation. that

that from will that. data when in we the Of PK studies get dictate we the the course, really achieve

Divya Rao

Alzheimer's. looking therapy just tau kind the tau we you're lends those think Or subpopulation? -- question think gene then And you at Should that vectorized specifically of to going X going after in programs the second both same sorry, specific after the that there's population? itself programs with my of a or of is patients do silencing kind

Todd Carter

I'd think tau unmet a and remains the Alzheimer's [ need fundamentally, ] with in is say I ahead strong patients there that, program disease. one,

amyloid [indiscernible] continues be think I there that we've progression. seen the from data disease to

so itself. excited foremost, ASO think first that all an in And we've advance is incredibly be antibody down incredibly and And tau. of tau in an an and we to important target and knocks

that's think I point of make. the would sort forward I most straight So,

Alfred Sandrock

Yes. the block add the Maybe the I that in of could of spread tau. case the spreading, to antibody is pathological meant

to started choose So, where spread the the want area has then we spread of the measure brain to would and patients essentially just an to. chose

going follow would the right? using X the we're knockdown, that's likely. approach in tracking Stage a going Stage so we're -- what or staging, knockdown be of an patients X program, And it BIIBXXX The able to case to ASO. to the be be And

study stage of we'll after And our model we're there, a including to suspect patients. that, lot So that. from going learn I the

Operator

comes with from Forseth Guggenheim Ry question Securities. Next

Ry Forseth

platform where central Could fit Debjit's indications, the for yield the potential you This and is addressing both specificity TRACER multi-organ of capsids there's with potentially to discuss from neuromuscular as such Ry DMX, pathology? team.

Alfred Sandrock

variations it that's start The Yes. look at with Friedreich's Todd In ways, trophic involves capsid is -- that heart. it additional activity. finds Well, way also DMX, -- in for applies I'll TRACER system and nervous in but to looks capsids endows finish. a the the an not we given Ataxia, -- some just which can the that, the

the of gets its for property AAVX cardiac works would our And pretty an its affects muscle, also the TRACER-derived all don't necessarily because the property So, to And be on retains the additional transducing capsid. own, capsid bring enhance of you hands, that if ideal muscle have heart since but the also well then that. heart. brain, the I heart, into by up getting way, DMX in

obviously choose can of we skeletal terms capsids In skeletal look that at we there, will and transduction, muscle, muscle do that. do

that we have Ataxia. way, Todd, that's the I why but started do haven't Friedreich's program, to... DMX you We by said with want a But,

Todd Carter

Sure.

tissues non-human look fact, actually have when CNS wide delivery disease, of we to needs do the different profile, parts build a the a And different given our identifying at target we're of capsid Different profile. for and primates selecting in we capsid any diseases different diseases, variety throughout even capsids. quite a relative So brain.

also We off-target tissues detargeting liver. look for for like the

out And evaluate of our kinds quite tissues. profiles are do so, we coming have that, that seeing number screens. we are And is different a of what capsid we of capsid

So what diseases. delivery like heart, deployed of families the greater being lesser brain off-targets. includes regions, the that to and and for that course, potentials different various that have different in muscle, or different for opportunities results And are places capsid

So to in other the I diseases opportunity the see think deliver CNS, well. TRACER opportunities the as answer is, for just we not but for, do

Operator

comes from with David Next question Citigroup.

Unknown Analyst

Shawn relates is question Citi. we anti-tau some that of ] SODX what [ is, therapy. filing? you have remaining speak to gating Biogen's the of factors question second your I This versus therapy potential IND program? And competitive curious, from can on gene silencing positioning the the team the are just to to David's to guess, get I'm one

Alfred Sandrock

maybe second on answer and question could answer Well, the question I'll on the then first tau, SODX. Toby

So, antibody directed have N-terminal that did BIIBXXX the an program were was program. not have terms producing mentioned. They against of Biogen, anti-tau in That a terminated as the acceptable. results they after Toby

results. C-terminal. Fundamentally, other one is N-terminal But that MTBR, the approach are expect already is, some the the yet. targeting do are, file the other XXXX. behind, a clinic however, and various will, the some we're and an vectorized because you in we the are, other We X different indicated, companies siRNA the But so -- clinic mid-domain, And None probably antibodies, we're way thinks program, company is the are so, not is epitope. Toby BIIBXXX know us, companies IND number to there everybody in if which great the of intracellular in as some anti-tau pursuing knocking against not just and again, epitopes. extracellular. it's very targeting N-terminal, that similar the targeting like all produce of would a at least both the directed sense in tau, forms in of targeting expression interesting to I it's down concept, that starting add that of

So in essentially nervous the it's system. of decreasing expression tau,

second want in So we relatively it that do equivalent you tau. Toby, the think, effect sense, produces, a take to on question?

Toby Ferguson

Sure. Maybe just our our program on that onetime to capsids, Biogen do, TRACER novel and IV with our is sort on of strategy that a I intrathecally I'd one of highlight administered, other the relatively program, add is tau before the point program, program course, targets. administrative pursuing of keeping in derisked with is

for On the programs, highlighted SOD program that's program, closed that as step what the I the IND. and that that, key the think moving program for program is forward we've we started the toxicology fundamentally we which main next

Operator

Olson Next comes question from with Jay Oppenheimer.

Unknown Analyst

is on or for This the Maybe Congrats from the like Jay. [indiscernible] X line on progress. X-part questions a us.

thinking there's we're to way liver about ALPL and a modality any detargeting just is step to behind TRACER new mechanism prioritize? enhance a are the forward of capsid further to for this binding, just secondly, the wondering I'm wondering Curious modalities. if for rationale like now First, particular liver looking the right you detargeting. And the

Alfred Sandrock

ask I'll question second to take So the one. and answer I'll Todd first the

Todd Carter

Sure.

many a we're can seeing with barrier. that X deliver our capsids have or too barrier. in less empirical And One, reported than is than capsids It's capsids parental mechanistically, do blood-brain deliver different the of don't capsid question something an they the detargeted I So variety and liver these that liver? deliver for across blood-brain from that the are answer the the cross observation to parts. was first that the capsids families, those elsewhere why effectively less that of this others this for

liver affect impact speculate, As can some that the is, delivery. of to the the can reasons it know we why? We of things subtle that capsid charge like changes

for criteria those the that, is of is, liver. any This capsids the our to we're observations that and again, something specifically looking off-target already forward choosing for part problems. that relating with reduce to the empirical selection from to other move we potential The is targeted are

Alfred Sandrock

quick to just And question second answer a on the ALPL.

now. to proteins ASOs not the correct, are transport and see to conjugating we at to and we if various whether oligonucleotides, testing antibodies And them we're yes, looking we're also across or doing using be such can as you're So binding interested can BBB. siRNAs. going ligands enzymes. and macromolecules And both therapeutic they them in get experiments We're ALPL those

Operator

question comes Truist. with Next Joon Lee from

Mehdi Goudarzi

Congrats for is on This Mehdi the progress. on Joon.

maybe So question us. picture for big a

time also, in XX field, do how to basically, space? Given the in this ensure in recent in also, And the to see especially TRACER leadership relation position AAVs you on of and you months? plan platform, to data, the next XX decorated future advances CNS-targeted AAVs, to your how

Alfred Sandrock

I That's we example, companies AAV of an Voyager scientists you motifs. multiple aware decorating, fact interesting as you the just just to look, pointed will, AAV, have there with, the not but for if that be pursuing TfR question. are other believe binding that the the and And modifying approach pioneered, out,

tissues And besides so, until in are the we don't more to is we than CNS? what I is, can involve would potentially, ones the the viable brain approaches going future, because Second which just earlier example, do know in other the experiments will target see you what work. that question, say diseases cell-type humans we're the several tropism. for but all those

want So tissue, it's certain target the cells. to not just we

sometimes sometimes And it's oligodendrocytes. glial neurons, cells, it's it's sometimes

types. And root only of detargeting, neuron. cell the toxicity, but it's ganglia potential there's then cells combination those Sometimes liver, also of a dorsal the other not such

why, as for and to high pretty you we for together, need think diseases. there's developed we're And profiles the of multiple we diseases said a be to when Todd be earlier, capsid going for add are capsids that each So that all bar. certain have going that's required I considering,

affecting in There's making and immunogenicity, variations the there capsid. that potentially we remember, manufacturability, for say issues of that's by that there's other example, built ways development into also and candidate I'd are immunogenicity Finally, criteria. should our

that in had. may innovation a the there's we and But I so, emphasize of occur we the cells transduction the which disease tailor think that to capsids lot also we need the want be And to I that the to fact need get to in. want to to to treat still

Operator

of from with The comes line the Genuity. Kulkarni next Sumant question Canaccord

Sumant Kulkarni

your what with tau? on programs one-and-done of silencing intracellular versus your you And the of therapy targeting approaches, So, anti-tau the gene program, of any extracellular stabilization? are potentially in given conceptually, cons and tau of pros are role aware tau microtubule downsides

Alfred Sandrock

ask or affecting that I'll in Well, my and you're implying maybe not safer, extracellular to then targeting you're Toby start the colleagues, not either as in you're I'll because Todd tau intracellular forms tau kind add. tau to all your say I affecting be would likely is and of particular. question of

-- So said, Toby antibodies have hand, what particularly other given, about the efficacy, questions failed. N-terminal are on there but the as

of And of in can the actually they're they reproduce. -- pretty viable, we actually knockdown, there's so, that. And knockout -- don't terms animals then first know all, tau are

BIIBXXX in will couple have the sense -- seems is study. there ago. is that years development, role the for think over those a be it And a doesn't tau. I'd patients to loss thing that idea of for studies started some hundreds there safety were we enroll the the that, some we're during tau of say fortunate of be other the going of certainly, though even to long-term, a because seem we is so, well-controlled And to actually into tolerance

terms have data clinic journey too. we safe the the our what's what the not. long-term down magnitude safety of tau have mean, is some of and and start the should enter the idea on ourselves. And time of then we'll by I expression knockdown, of as perhaps by then Toby? So also knocking we in

Toby Ferguson

just human least have knockdown don't genetic been to tau suggests has particular, the in of understood experience far, well I think data some of add. data, that mean, that, the tolerated. I maybe as the we much so I that Al, really at

based and tau data. need quite of with forms given spreading important. its very course, in And the think all And do a Of that model, tau, totality we've think knockdown address longer-term have you for pathologic form really idea is seen. the tau thing program, we'll I really, antibody and to knockdown our reasonable that the we the to it's of of we targeted is on sort see supersede -- the

think could that's important. they be complementary each so, think we essentially And other. I And to

Todd Carter

BIIBXXX date, a what add will with although the just to that all will described animals little in I benign. that knockout supersede I human preclinical looked preclinical, bit, tau addition studies to add Al ultimately remarkably data think I'll the anything has

have on so, non-human primates done we've have that conferences. at as our mouse looked internally people rodent And about species. talked Other this as We've in studies in well people reported this.

far, so And benign. reduction remarkably therapy-like quite using has approaches gene seen of tau gene or therapy

the experiment. pretty things you knockdown to never But So look ultimate do know date, regard positive until you with to human risk.

Operator

The Yanan next question Securities. comes from Zhu with Wells Fargo

Kuan-Hung Lin

Yanan. for is on Kuan This

question I the program, siRNA siRNA. have So on quick sorry a

a you And there for data? the NHP previously the mentioned see strategy is we potential that with combo may when antibody. So

would Or thoughts the So on seek programs? And that? of updated antibody approval would you first? you synchronize any the

Alfred Sandrock

Toby first answer second part to I'll ask and the Todd part. to question of answer the the

Todd Carter

Yes.

toward For candidate on in that we've no development XXXX. ongoing drive We've given to guidance The to question, expect identification. first of the part we is have we when data. experiments given have guidance that the IND those

Toby Ferguson

On the remains programs, the I to about second unmet question, context part what say, would Alzheimer's with for a important question the disease. of asked most that, is fundamentally strong what's a you need think people I synchronizing there

our tau antibody program, of lead, data we with so, positive the move if course which is in ] would had we for we certainly -- that And forward [ program.

Kuan-Hung Lin

Got it. And a quick follow-up.

So antibody. hypothetical for it's the a question

Braak early-stage spread tau to the all be able stop cells, you patients, enough to the save would of between II if So Stage are patients? such that as

Toby Ferguson

it's question. reasonable fundamentally, very think a I

elated I think would, saw that. we of we if course, be

is what on is pathology tau spread program. We'll of clinic. it we tau from figure to tau this I intent have of understand in think out PET that, the and based the the

Operator

The next Securities. question comes from Laura Chico with Wedbush

Laura Chico

talk other ask a few wanted up mix to about to type programs, you for intervention. little Friedreich's any wondering what's radar in the would just for that bit but you have gene And and us that here. essentially, milestones should 'XX? potential a to Can we quick there related therapy little you been appropriate of therapeutic to efforts these kind I a of remind the questions window Any could the how identify. ongoing follow-up. it you Wondering GBAX there. And spaces, on about then be seeking two ataxia the patients remaining our about think have just one if color

Toby Ferguson

remind of that the for Friedreich's these partner the they think I that own development programs, program. I'll ataxia So and work are programs

to and programs I populations, that such think other approval, age if younger some broad you [indiscernible], have the at patients. they've looked look adult both gotten as

So a paved, there I comment path the been on think think we that's then [indiscernible]. And really milestones, that don't sits milestones. fundamentally, I there is with this just but

Alfred Sandrock

would ever just approved. add FA, NrfX The on that It's great FA drug mechanism of first that action. say, activator. an also the it's I for was

I think to think going would it's the our I be drug -- to only add efficacy.

because so, completely action, different of is frataxin. And they're ours replacing mechanisms

I'll then to Neurocrine the -- more to questions. you ask Laura that. So a And just ask say specific

Operator

concludes participation. this presentation. once you today's gentlemen, Thank and Ladies your again for

disconnect. now may You

Voyager Therapeutics (VYGR) 6 Aug 242024 Q2 Earnings call transcript